# Luca Giovanella

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 385 papers | 6,254 citations | 39 h-index | 55 g-index |
| 422 ext. papers | 7,917 ext. citations | 4.4 avg, IF | 6.36 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 385 | Thyroid Functional and Molecular Imaging.. *Presse Medicale*, **2022**, 104116 | 2.2 | 0 |
| 384 | Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.. *Cancers*, **2022**, 14, | 6.6 | 2 |
| 383 | CT evaluation of lung infiltrates in the two months preceding the Coronavirus disease 19 pandemic in Canton Ticino (Switzerland): were there suspicious cases before the official first case?. *Radiologia Medica*, **2022**, 127, 360 | 6.5 | 2 |
| 382 | Unusual [18F]-fluorocholine uptake in "hot" thyroid nodule and ipsilateral parathyroid adenoma.. *Endocrine*, **2022**, 1 | 4 | |
| 381 | Malignant thyroid nodule topography as additional risk factor for lymph-node metastases in differentiated thyroid cancer patients.. *European Archives of Oto-Rhino-Laryngology*, **2022**, 1 | 3.5 | |
| 380 | Diagnostic Performance of 99mTc-Methoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter Study. *Diagnostics*, **2022**, 12, 1358 | 3.8 | |
| 379 | Clinical performance of calcitonin and procalcitonin Elecsys immunoassays in patients with medullary thyroid carcinoma. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 743-747 | 5.9 | 5 |
| 378 | Global FT4 immunoassay standardization: an expert opinion review. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1013-1023 | 5.9 | 5 |
| 377 | Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for postoperative follow-up. *Expert Review of Endocrinology and Metabolism*, **2021**, 1-7 | 4.1 | 4 |
| 376 | Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. *Hematological Oncology*, **2021**, | 1.3 | 2 |
| 375 | Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. *Clinical and Translational Imaging*, **2021**, 9, 1-8 | 2 | 15 |
| 374 | The Role of 2-[18F]-FDG PET/CT in Detecting Richter Transformation in Chronic Lymphocytic Leukemia: A Systematic Review. *Radiation*, **2021**, 1, 65-76 | | 0 |
| 373 | Diagnostic Role of F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review. *Diagnostics*, **2021**, 11, | 3.8 | 8 |
| 372 | An ectopic, dysmorphic and atypical parathyroid adenoma. *Endocrine*, **2021**, 74, 200-201 | 4 | 0 |
| 371 | Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1569-1573 | 5.9 | 3 |
| 370 | Medical treatment of thyrotoxicosis. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 65, 113-123 | 1.4 | 3 |
| 369 | Update on diagnosis and treatment of hyperthyroidism. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 65, 89-90 | 1.4 | |

| | | | |
|---|---|---|---|
| 368 | Radioiodine therapy of Graves' disease. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 65, 132-137 | 1.4 | 1 |
| 367 | The EANM practice guidelines for parathyroid imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2801-2822 | 8.8 | 22 |
| 366 | Usefulness of I-spect/ct to assess the response to initial therapy in differentiated thyroid cancer patients. *Endocrine*, **2021**, 74, 193-196 | 4 | 2 |
| 365 | SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives. *Expert Review of Clinical Immunology*, **2021**, 17, 737-759 | 5.1 | 21 |
| 364 | A multicenter survey of current practices of 99mTc-methoxy-isobutyl-isonitrile (MIBI) imaging for the diagnosis of thyroid nodules: more standardization is essential. *Clinical and Translational Imaging*, **2021**, 9, 413-422 | 2 | 1 |
| 363 | The new Roche Elecsys TSH assay conforms with current IFCC C-STFT standards. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, e445-e448 | 5.9 | 0 |
| 362 | A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. *Thyroid*, **2021**, 31, 1009-1019 | 6.2 | 7 |
| 361 | Radiomics Analysis of [F]-Fluorodeoxyglucose-Avid Thyroid Incidentalomas Improves Risk Stratification and Selection for Clinical Assessment. *Thyroid*, **2021**, 31, 88-95 | 6.2 | 12 |
| 360 | Higher thyroid hormone levels and cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 808-821 | 8.8 | 4 |
| 359 | How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 822-830 | 8.8 | 2 |
| 358 | Will F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging?. *Endocrine* , **2021**, 71, 285-297 | 4 | 17 |
| 357 | The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis. *Reviews in Endocrine and Metabolic Disorders*, **2021**, 22, 453-460 | 10.5 | 19 |
| 356 | Determining an energy threshold for optimal volume reduction of benign thyroid nodules treated by radiofrequency ablation. *European Radiology*, **2021**, 31, 5189-5197 | 8 | 10 |
| 355 | Free-thyroxine standardization: while well serving our patients today. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, e225-e226 | 5.9 | 1 |
| 354 | Molecular Imaging for Thyrotoxicosis and Thyroid Nodules. *Journal of Nuclear Medicine*, **2021**, 62, 20S-25S | 8.9 | 2 |
| 353 | A spotlight on redifferentiation strategies and target modulation in differentiated thyroid cancer. *Clinical and Translational Imaging*, **2021**, 9, 405-408 | 2 | |
| 352 | Low free-T3 serum levels and prognosis of COVID-19: systematic review and meta-analysis. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1906-1913 | 5.9 | 6 |
| 351 | Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis. *Pharmaceuticals*, **2021**, 14, | 5.2 | 6 |

| | | | |
|---|---|---|---|
| 350 | Procalcitonin as an Alternative Tumor Marker of Medullary Thyroid Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 3634-3643 | 5.6 | 2 |
| 349 | MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE. *Journal of Nuclear Medicine*, **2021**, | 8.9 | 1 |
| 348 | Isthmus topography is a risk factor for persistent disease in patients with differentiated thyroid cancer. *European Journal of Endocrinology*, **2021**, 185, 397-404 | 6.5 | 4 |
| 347 | Comment on: Report of One Case of Malignancy Among 17 Autonomous Thyroid Nodules in Children and Adolescents. *Journal of Paediatrics and Child Health*, **2021**, | 1.3 | |
| 346 | Radiomics analysis improves FDG PET/CT-based risk stratification of cytologically indeterminate thyroid nodules. *Endocrine*, **2021**, 1 | 4 | 4 |
| 345 | Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2466-2475 | 8.8 | 7 |
| 344 | Is isthmic enucleo-resection a reliable treatment for isthmic differentiated thyroid carcinoma? A note of caution. *Journal of Endocrinological Investigation*, **2020**, 43, 1829-1830 | 5.2 | 1 |
| 343 | Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer. *Journal of Nuclear Medicine*, **2020**, 61, 375-396 | 8.9 | 7 |
| 342 | Indeterminate thyroid nodules. The role of F-FDG PET/CT in the "era" of ultrasonography risk stratification systems and new thyroid cytology classifications. *Endocrine*, **2020**, 69, 553-561 | 4 | 10 |
| 341 | Prevalence and clinical significance of incidental 18F-FDG uptake in the pituitary. *Clinical and Translational Imaging*, **2020**, 8, 237-242 | 2 | 1 |
| 340 | Iperparatiroidismo primitivo con indicazione chirurgica e scintigrafia non dirimente: sicurezza e performance diagnostica del PTH su eluato. *L Endocrinologo*, **2020**, 21, 25-29 | 0 | |
| 339 | Detection of thyroiditis on PET/CT imaging: a systematic review. *Hormones*, **2020**, 19, 341-349 | 3.1 | 4 |
| 338 | Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System. *Thyroid*, **2020**, 30, 713-719 | 6.2 | 15 |
| 337 | Different Formulations of Levothyroxine for Treating Hypothyroidism: A Real-Life Study. *International Journal of Endocrinology*, **2020**, 2020, 4524759 | 2.7 | 6 |
| 336 | Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?. *Endocrine*, **2020**, 67, 281-290 | 4 | 11 |
| 335 | Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference. *Radiologia Medica*, **2020**, 125, 406-415 | 6.5 | 18 |
| 334 | FNA indication according to ACR-TIRADS, EU-TIRADS and K-TIRADS in thyroid incidentalomas at F-FDG PET/CT. *Journal of Endocrinological Investigation*, **2020**, 43, 1607-1612 | 5.2 | 9 |
| 333 | SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. *Blood Advances*, **2020**, 4, 1082-1092 | 7.8 | 21 |

| | | | |
|---|---|---|---|
| 332 | Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis. *Journal of Nuclear Medicine*, **2020**, 61, 1730-1735 | 8.9 | 3 |
| 331 | Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: a meta-analysis. *European Journal of Endocrinology*, **2020**, 183, 255-264 | 6.5 | 13 |
| 330 | ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer. *European Journal of Endocrinology*, **2020**, 183, G41-G48 | 6.5 | 25 |
| 329 | Evidence-Based Data About Prevalence and Risk of Malignancy of Thyroid Incidentalomas Detected by Different PET Radiopharmaceuticals. *Current Radiopharmaceuticals*, **2020**, 13, 89-93 | 1.8 | 6 |
| 328 | Copper, PET/CT and prostate cancer: a systematic review of the literature. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 64, 382-392 | 1.4 | 2 |
| 327 | 18F-FET **2020**, 83-88 | | |
| 326 | Introduction to Different PET Radiopharmaceuticals and Hybrid Modalities (PET/CT and PET/MRI) **2020**, 3-15 | | |
| 325 | Prognostic and predictive value of nuclear imaging in endocrine oncology. *Endocrine*, **2020**, 67, 9-19 | 4 | 4 |
| 324 | Variations in radioiodine ablation: decision-making after total thyroidectomy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 554-560 | 8.8 | 2 |
| 323 | Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. *Reviews in Endocrine and Metabolic Disorders*, **2020**, 21, 5-16 | 10.5 | 64 |
| 322 | Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 55 |
| 321 | Thermal ablation meta-analysis: the need of careful appraisal of meta-analysis methodology. *Endocrine*, **2020**, 67, 270-271 | 4 | |
| 320 | Laboratory Investigation of the 900-km Lapland Extreme Challenge. *Annals of Laboratory Medicine*, **2020**, 40, 92-94 | 3.1 | |
| 319 | Risk of Malignancy (ROM) of Thyroid FNA Diagnosed as Suspicious for Malignancy or Malignant: an Institutional Experience with Systematic Review and Meta-Analysis of Literature. *Endocrine Pathology*, **2020**, 31, 52-56 | 4.2 | 6 |
| 318 | Diagnostic testing for Graves' or non-Graves' hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. *Clinical Endocrinology*, **2020**, 92, 169-178 | 3.4 | 22 |
| 317 | Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis. *Endocrine Pathology*, **2020**, 31, 57-66 | 4.2 | 7 |
| 316 | Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. *Current Opinion in Oncology*, **2020**, 32, 7-12 | 4.2 | 6 |
| 315 | F-Fluoride (F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines!. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 527-528 | 8.8 | 3 |

| | | | |
|---|---|---|---|
| 314 | Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma?. *Cancer Cytopathology*, **2020**, 128, 250-259 | 3.9 | 35 |
| 313 | Significance of "de novo" appearance of thyroglobulin antibodies in patients with differentiated thyroid cancer. *International Journal of Biological Markers*, **2020**, 35, 41-49 | 2.8 | 2 |
| 312 | Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts. *Endocrine*, **2020**, 70, 280-291 | 4 | 19 |
| 311 | Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. *Hematological Oncology*, **2020**, 38, 715-725 | 1.3 | 8 |
| 310 | Diagnosis, Treatment Response, and Prognosis: The Role of F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with I-mIBG Scan: The First Prospective Study. *Journal of Nuclear Medicine*, **2020**, 61, 367-374 | 8.9 | 13 |
| 309 | Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 78-83 | 8.8 | 16 |
| 308 | The role of systematic review and meta-analysis in modern cytopathology. *Cancer Cytopathology*, **2020**, 128, 89-91 | 3.9 | 2 |
| 307 | Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: A systematic review and meta-analysis. *Endocrine*, **2020**, 67, 35-43 | 4 | 77 |
| 306 | Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. *Journal of Endocrinological Investigation*, **2020**, 43, 219-229 | 5.2 | 27 |
| 305 | EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 61-77 | 8.8 | 36 |
| 304 | Ultrasound systems for risk stratification of thyroid nodules prompt inappropriate biopsy in autonomously functioning thyroid nodules. *Clinical Endocrinology*, **2020**, 93, 67-75 | 3.4 | 15 |
| 303 | Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules. *Gland Surgery*, **2019**, 8, S118-S125 | 2.2 | 8 |
| 302 | Performance of F-FDG PET/CT in Selecting Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytology for Surgery. A Systematic Review and a Meta-Analysis. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 6 |
| 301 | Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer. *Clinical Chemistry and Laboratory Medicine*, **2019**, 58, 130-137 | 5.9 | 7 |
| 300 | F-FDG-PET/CT Imaging in Advanced Glottic Cancer: A Tool for Clinical Decision in Comparison with Conventional Imaging. *Contrast Media and Molecular Imaging*, **2019**, 2019, 4051206 | 3.2 | 0 |
| 299 | Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 38 |
| 298 | Diagnostic Performance of PET or PET/CT Using F-FDG Labeled White Blood Cells in Infectious Diseases: A Systematic Review and a Bivariate Meta-Analysis. *Diagnostics*, **2019**, 9, | 3.8 | 11 |
| 297 | Detection rate of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: an updated systematic review and meta-analysis. *Clinical and Translational Imaging*, **2019**, 7, 237-253 | 2 | 2 |

| | | | |
|---|---|---|---|
| 296 | Detection Rate of F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. *Cancers*, **2019**, 11, | 6.6 | 49 |
| 295 | An unsuspicious thyroid nodule with fatal outcome. *Hormones*, **2019**, 18, 321-324 | 3.1 | 4 |
| 294 | Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis. *Endocrine*, **2019**, 64, 456-468 | 4 | 7 |
| 293 | A multicentre validation study for the EU-TIRADS using histological diagnosis as a gold standard. *Clinical Endocrinology*, **2019**, 91, 340-347 | 3.4 | 25 |
| 292 | Ga-PSMA PET thyroid incidentalomas. *Hormones*, **2019**, 18, 145-149 | 3.1 | 17 |
| 291 | Re: "Diagnostic Performance of Technetium-99m Methoxy-Isobutyl-Isonitrile for Differentiation of Malignant Thyroid Nodules: A Systematic Review and Meta-Analysis" by Kim . ( 2018;28:1339-1348). *Thyroid*, **2019**, 29, 896-897 | 6.2 | 1 |
| 290 | PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art. *Reviews in Endocrine and Metabolic Disorders*, **2019**, 20, 47-64 | 10.5 | 19 |
| 289 | Controversies, Consensus, and Collaboration in the Use of I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European | 6.2 | 119 |
| 288 | Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1185-1191 | 5.9 | 3 |
| 287 | Thyroid cancer recurrence in the HiLo trial. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 252 | 18.1 | |
| 286 | High-intensity focused ultrasound (HIFU) for benign thyroid nodules: 2-year follow-up results. *Endocrine*, **2019**, 65, 312-317 | 4 | 27 |
| 285 | Role of F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients. *Thyroid*, **2019**, 29, 549-556 | 6.2 | 4 |
| 284 | Tc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities. *Endocrinology and Metabolism*, **2019**, 34, 63-69 | 3.5 | 2 |
| 283 | Thyroid Imaging **2019**, 545-564 | | 1 |
| 282 | Dedicated neck F-FDG PET/CT: An additional tool for risk assessment in thyroid nodules at ultrasound intermediate risk. *Clinical Endocrinology*, **2019**, 90, 737-743 | 3.4 | 4 |
| 281 | Impact of F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. *Frontiers in Medicine*, **2019**, 6, 336 | 4.9 | 15 |
| 280 | Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 751-765 | 8.8 | 79 |
| 279 | EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2514-2525 | 8.8 | 45 |

| | | | |
|---|---|---|---|
| 278 | Use of anti-thyroid drugs in patients with hyperthyroidism: a case for shared decision-making. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2408-2409 | 8.8 | 3 |
| 277 | Prognosis of patients with differentiated thyroid carcinomas having a preoperative cytological report of indeterminate at low or high risk. A multicenter study. *Endocrine*, **2019**, 66, 557-562 | 4 | 1 |
| 276 | Long-Term Efficacy of a Single Session of RFA for Benign Thyroid Nodules: A Longitudinal 5-Year Observational Study. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 3751-3756 | 5.6 | 55 |
| 275 | The impact of biotin interference on laboratory testing and patient diagnosis in clinical practice. *International Journal of Pharmacokinetics*, **2019**, 4, IPK01 | 0.3 | 0 |
| 274 | Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis. *European Journal of Endocrinology*, **2019**, 180, 177-187 | 6.5 | 11 |
| 273 | MANAGEMENT OF ENDOCRINE DISEASE: The role of rhTSH in the management of differentiated thyroid cancer: pros and cons. *European Journal of Endocrinology*, **2019**, 181, R133-R145 | 6.5 | 10 |
| 272 | Primary hyperparathyroidism with surgical indication and negative or equivocal scintigraphy: safety and reliability of PTH washout. A systematic review and meta-analysis. *European Journal of Endocrinology*, **2019**, 181, 245-253 | 6.5 | 9 |
| 271 | Impact of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) on risk of malignancy in patients undergoing lobectomy/thyroidectomy for suspected malignancy or malignant fine-needle aspiration cytology findings: a systematic review and meta-analysis. *European Journal of Endocrinology*, **2019**, 181, 389-396 | 6.5 | 15 |
| 270 | Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. *American Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 9, 127-139 | 2.2 | 22 |
| 269 | Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 63, 229-234 | 1.4 | 4 |
| 268 | Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. *Swiss Medical Weekly*, **2019**, 149, w14700 | 3.1 | 7 |
| 267 | Correlation between PSA kinetics and detection rate of PSMA-PET in the setting of biochemical recurrent prostate cancer: A systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2019**, 37, 71-71 | 2.2 | |
| 266 | Advanced differentiated thyroid cancer: when to stop radioiodine?. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 63, 267-270 | 1.4 | 2 |
| 265 | Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis. *Diagnostics*, **2019**, 10, | 3.8 | 10 |
| 264 | Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 1334-1344 | 8.8 | 8 |
| 263 | Multimodal therapy of advanced differentiated thyroid cancer, with emphasis on the role of radioiodine. *Clinical and Translational Imaging*, **2019**, 7, 427-435 | 2 | 1 |
| 262 | Additional value of integrated F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 766-775 | 8.8 | 40 |
| 261 | Euthyroid Graves' disease with spurious hyperthyroidism: a diagnostic challenge. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, e94-e96 | 5.9 | 3 |

| | | | |
|---|---|---|---|
| 260 | Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis. *European Journal of Clinical Investigation*, **2019**, 49, e13063 | 4.6 | 31 |
| 259 | Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis. *Thyroid*, **2019**, 29, 222-228 | 6.2 | 29 |
| 258 | Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). *Journal of Endocrinological Investigation*, **2019**, 42, 745-756 | 5.2 | 36 |
| 257 | Thyroglobulin and Tg Antibodies **2019**, 655-671 | | |
| 256 | F18-choline/C11-choline PET/CT thyroid incidentalomas. *Endocrine*, **2019**, 64, 203-208 | 4 | 8 |
| 255 | Italian consensus for the classification and reporting of thyroid cytology: the risk of malignancy between indeterminate lesions at low or high risk. A systematic review and meta-analysis. *Endocrine*, **2019**, 63, 430-438 | 4 | 23 |
| 254 | Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1218-1223 | 8.8 | 4 |
| 253 | Re: Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a). *Clinical Nuclear Medicine*, **2018**, 43, 631-632 | 1.7 | |
| 252 | Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and I Ablation. *Thyroid*, **2018**, 28, 722-728 | 6.2 | 18 |
| 251 | Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules. *European Journal of Clinical Investigation*, **2018**, 48, e12934 | 4.6 | 22 |
| 250 | Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy. *Journal of Nuclear Medicine*, **2018**, 59, 723-725 | 8.9 | 12 |
| 249 | Histologic Outcome of Indeterminate Thyroid Nodules Classified at Low or High Risk. *Endocrine Pathology*, **2018**, 29, 75-79 | 4.2 | 6 |
| 248 | High-intensity focused ultrasound (HIFU) therapy for benign thyroid nodules without anesthesia or sedation. *Endocrine*, **2018**, 61, 210-215 | 4 | 23 |
| 247 | Unusual case of tumor of unknown origin found by 18 F-FDG PET/CT: Metastatic clear cell carcinoma of the thyroid gland. *Revista Espanola De Medicina Nuclear E Imagen Molecular*, **2018**, 37, 54-56 | 0.1 | |
| 246 | Procalcitonin: Are We Ready for Clinical Use? **2018**, 151-157 | | |
| 245 | Circulating Mucins and Cytokeratins in Aggressive Thyroid Cancers **2018**, 175-189 | | 1 |
| 244 | Measurement of Thyroid Tumor Markers on Fine-Needle Washouts **2018**, 193-200 | | |
| 243 | Thyroglobulin and Thyroglobulin Antibodies **2018**, 65-91 | | |

| | | | |
|---|---|---|---|
| 242 | American Thyroid Association ultrasound system for the initial assessment of thyroid nodules: Use in stratifying the risk of malignancy of indeterminate lesions. *Head and Neck*, **2018**, 40, 722-727 | 4.2 | 20 |
| 241 | Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, e191-e193 | 5.9 | 7 |
| 240 | Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. *International Journal of Biological Markers*, **2018**, 33, 156-160 | 2.8 | 13 |
| 239 | Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. *Blood*, **2018**, 132, 179-186 | 2.2 | 38 |
| 238 | Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes. *Clinical Physiology and Functional Imaging*, **2018**, 38, 4-9 | 2.4 | 4 |
| 237 | Unusual case of tumor of unknown origin found by F-FDG PET/CT: Metastatic clear cell carcinoma of the thyroid gland. *Revista Espanola De Medicina Nuclear E Imagen Molecular*, **2018**, 37, 54-56 | 0.4 | |
| 236 | Treatment of benign thyroid nodules by high intensity focused ultrasound (HIFU) at different acoustic powers: a study on in-silico phantom. *Endocrine*, **2018**, 59, 506-509 | 4 | 16 |
| 235 | Multicentre clinical evaluation of the new highly sensitive Elecsys thyroglobulin II assay in patients with differentiated thyroid carcinoma. *Clinical Endocrinology*, **2018**, 88, 295-302 | 3.4 | 8 |
| 234 | Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. *Endocrinology and Metabolism*, **2018**, 33, 204-210 | 3.5 | 8 |
| 233 | Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. *Frontiers in Endocrinology*, **2018**, 9, 10 | 5.7 | 37 |
| 232 | Thyroxine Treatment With Softgel Capsule Formulation: Usefulness in Hypothyroid Patients Without Malabsorption. *Frontiers in Endocrinology*, **2018**, 9, 118 | 5.7 | 15 |
| 231 | Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. *Frontiers in Endocrinology*, **2018**, 9, 224 | 5.7 | 19 |
| 230 | Fine-needle aspiration in all thyroid incidentalomas at F-FDG PET/CT: Can EU-TIRADS revise the dogma?. *Clinical Endocrinology*, **2018**, 89, 642-648 | 3.4 | 8 |
| 229 | Tomografia a emissione di positroni con 18F-fluorodesossiglucosio nel carcinoma tiroideo radioiodio-refrattario. *L Endocrinologo*, **2018**, 19, 15-20 | 0 | |
| 228 | Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules. *Clinical Endocrinology*, **2018**, 89, 219-225 | 3.4 | 18 |
| 227 | Reliability of core needle biopsy as a second-line procedure in thyroid nodules with an indeterminate fine-needle aspiration report: a systematic review and meta-analysis. *Ultrasonography*, **2018**, 37, 121-128 | 4.3 | 7 |
| 226 | Undetectable or low (. *Oncotarget*, **2018**, 9, 17491-17500 | 3.3 | 21 |
| 225 | Imaging in primary hyperparathyroidism: focus on the evidence-based diagnostic performance of different methods. *Minerva Endocrinology*, **2018**, 43, 133-143 | 2.5 | 28 |

| | | | |
|---|---|---|---|
| 224 | Early post-treatment risk stratification of differentiated thyroid cancer: comparison of three high-sensitive Tg assays. *European Journal of Endocrinology*, **2018**, 178, 75-82 | 6.5 | 10 |
| 223 | Performance of Italian Consensus for the Classification and Reporting of Thyroid Cytology (ICCRTC) in discriminating indeterminate lesions at low and high risk of malignancy. A systematic review and meta-analysis. *Endocrine*, **2018**, 60, 31-35 | 4 | 14 |
| 222 | Recent Developments of 18F-FET PET in Neuro-oncology. *Current Medicinal Chemistry*, **2018**, 25, 3061-3073 | 4.3 | 31 |
| 221 | Uso della procalcitonina come marker del carcinoma midollare tiroideo. *Rivista Italiana Della Medicina Di Laboratorio*, **2018**, 14, 198-200 | 1.1 | |
| 220 | Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves' disease. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 58-64 | 5.9 | 34 |
| 219 | Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry. *Endocrine Pathology* , **2017**, 28, 71-74 | 4.2 | 6 |
| 218 | One-stop-shop radioiodine dosimetry in patients with Graves' disease. *Endocrine*, **2017**, 56, 220-221 | 4 | 1 |
| 217 | High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas. *European Journal of Endocrinology*, **2017**, 176, 497-504 | 6.5 | 14 |
| 216 | Radionuclide Imaging of Medullary Thyroid Carcinoma **2017**, 381-399 | | |
| 215 | Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. *British Journal of Haematology*, **2017**, 178, 588-591 | 4.5 | 15 |
| 214 | Letter to the Editor: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation". *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1783-1784 | 5.6 | 1 |
| 213 | Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1995-2001 | 5.9 | 10 |
| 212 | Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2113-2114 | 5.6 | 4 |
| 211 | Columnar cell variant of papillary thyroid carcinoma: Cytomorphological characteristics of 11 cases with histological correlation and literature review. *Cancer Cytopathology*, **2017**, 125, 389-397 | 3.9 | 20 |
| 210 | Real-time elastography in autonomously functioning thyroid nodules: relationship with TSH levels, scintigraphy, and ultrasound patterns. *Endocrine*, **2017**, 58, 488-494 | 4 | 12 |
| 209 | Accuracy of international ultrasound risk stratification systems in thyroid lesions cytologically classified as indeterminate. *Diagnostic Cytopathology*, **2017**, 45, 113-117 | 1.4 | 32 |
| 208 | Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 926-934 | 8.8 | 7 |
| 207 | Prevalence and clinical significance of focal incidental 18F-FDG uptake in different organs: an evidence-based summary. *Clinical and Translational Imaging*, **2017**, 5, 525-532 | 2 | 8 |

| | | | |
|---|---|---|---|
| 206 | METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.. *Hematological Oncology*, **2017**, 35, 60-61 | 1.3 | 2 |
| 205 | Differentiating malignant from benign thyroid nodules with indeterminate cytology by Tc-MIBI scan: a new quantitative method for improving diagnostic accuracy. *Scientific Reports*, **2017**, 7, 6147 | 4.9 | 15 |
| 204 | Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer. *Scientific Reports*, **2017**, 7, 7359 | 4.9 | 8 |
| 203 | Only a Rapid Complete Biochemical Remission After 131I-Therapy is Associated with an Unimpaired Life Expectancy in Differentiated Thyroid Cancer. *Hormone and Metabolic Research*, **2017**, 49, 860-868 | 3.1 | 3 |
| 202 | Clinical role and accuracy of 18F-FDG PET in evaluating disease activity in patients with chronic inflammatory bowel disease: an updated systematic review and a bivariate meta-analysis. *Clinical and Translational Imaging*, **2017**, 5, 303-313 | 2 | 1 |
| 201 | Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 914-925 | 5.9 | 24 |
| 200 | Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 42-49 | 4 | 21 |
| 199 | Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis. *International Journal of Molecular Sciences*, **2017**, 18, | 6.3 | 19 |
| 198 | Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. *Hormones*, **2017**, 16, 362-372 | 3.1 | 10 |
| 197 | DIAGNOSIS OF ENDOCRINE DISEASE: High-yield thyroid fine-needle aspiration cytology: an update focused on ancillary techniques improving its accuracy. *European Journal of Endocrinology*, **2016**, 174, R53-63 | 6.5 | 15 |
| 196 | Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis. *Head and Neck*, **2016**, 38 Suppl 1, E2159-72 | 4.2 | 62 |
| 195 | Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer. *Endocrine Journal*, **2016**, 63, 367-73 | 2.9 | 0 |
| 194 | Searching for the most effective thyrotropin (TSH) threshold to rule-out autonomously functioning thyroid nodules in iodine deficient regions. *Endocrine*, **2016**, 54, 757-761 | 4 | 24 |
| 193 | (99m)Tc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology. *Thyroid*, **2016**, 26, 1101-9 | 6.2 | 30 |
| 192 | Malignant Mucous Cells in a Thyroid Aspirate: Looking for a Source. *Endocrine Pathology*, **2016**, 27, 79-82 | 4.2 | 1 |
| 191 | (99m)Tc-MIBI Uptake in a Thyroid Adenoma with Diffuse Adipose Metaplasia. *Nuclear Medicine and Molecular Imaging*, **2016**, 50, 362-364 | 1.9 | |
| 190 | Molecular imaging with (99m)Tc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1018-26 | 8.8 | 39 |
| 189 | Hashimoto's encephalopathy: A rare proteiform disorder. *Autoimmunity Reviews*, **2016**, 15, 466-76 | 13.6 | 57 |

| | | | |
|---|---|---|---|
| 188 | Thyroid nodules with indeterminate cytology: prospective comparison between 18F-FDG-PET/CT, multiparametric neck ultrasonography, 99mTc-MIBI scintigraphy and histology. *European Journal of Endocrinology*, **2016**, 174, 693-703 | 6.5 | 46 |
| 187 | Limited Benefit of Additional Contrast-Enhanced CT to End-of- Treatment PET-CT Evaluation in Patients with Follicular Lymphoma. *Blood*, **2016**, 128, 5925-5925 | 2.2 | 1 |
| 186 | Medullary Thyroid Carcinoma **2016**, 83-88 | | |
| 185 | Thyroid Autonomy **2016**, 47-51 | | |
| 184 | Nuclear Medicine Techniques **2016**, 13-19 | | |
| 183 | Graves Disease **2016**, 41-45 | | |
| 182 | Differentiated Thyroid Carcinoma **2016**, 73-82 | | |
| 181 | HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin. *International Journal of Molecular Sciences*, **2016**, 17, | 6.3 | 7 |
| 180 | Serum markers measured in FNA fluids of medullary thyroid carcinoma occurring as a cyst. *International Journal of Biological Markers*, **2016**, 31, e224-7 | 2.8 | 5 |
| 179 | A rare case of idiopathic granulomatous hepatitis presenting as tumoral lesion detected by 18F-FDG-PET/CT. *Annals of Hepatology*, **2016**, 15, 121-2 | 3.1 | 1 |
| 178 | BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: a systematic review and meta-analysis. *Clinical Endocrinology*, **2016**, 84, 315-20 | 3.4 | 38 |
| 177 | BRAF (V600E) mutation in isthmic malignant thyroid nodules. *Clinical Endocrinology*, **2016**, 84, 152-3 | 3.4 | 4 |
| 176 | Hthle Cells Adenoma of the Thyroid with Post-surgical Implants in the Neck: Clinical, Morphological, and Molecular Analysis of Three Cases. *Endocrine Pathology*, **2016**, 27, 338-345 | 4.2 | 2 |
| 175 | Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review. *Diagnostic Cytopathology*, **2016**, 44, 45-51 | 1.4 | 40 |
| 174 | Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. *European Archives of Oto-Rhino-Laryngology*, **2015**, 272, 3617-26 | 3.5 | 20 |
| 173 | Differentiated thyroid cancer patients with a previous indeterminate (Thy 3) cytology have a better prognosis than those with suspicious or malignant FNAC reports. *Endocrine*, **2015**, 49, 191-5 | 4 | 15 |
| 172 | Preoperative measurement of serum thyroglobulin to predict malignancy in thyroid nodules: a systematic review. *Hormone and Metabolic Research*, **2015**, 47, 247-52 | 3.1 | 26 |
| 171 | Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. *Endocrine-Related Cancer*, **2015**, 22, R157-64 | 5.7 | 41 |

| | | | |
|---|---|---|---|
| 170 | Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 1507-14 | 5.9 | 52 |
| 169 | Prevalence of normal TSH value among patients with autonomously functioning thyroid nodule. *European Journal of Clinical Investigation*, **2015**, 45, 739-44 | 4.6 | 41 |
| 168 | Multicentre study of 18F-FDG-PET/CT prostate incidental uptake. *Japanese Journal of Radiology*, **2015**, 33, 538-46 | 2.9 | 7 |
| 167 | PET imaging in ectopic Cushing syndrome: a systematic review. *Endocrine*, **2015**, 50, 297-305 | 4 | 28 |
| 166 | Mycosis Fungoides Involving the Lungs Detected by 18F-FDG PET/CT. *Archivos De Bronconeumologia*, **2015**, 51, 521-522 | 0.7 | |
| 165 | Reliability of real-time elastography to diagnose thyroid nodules previously read at FNAC as indeterminate: a meta-analysis. *Endocrine*, **2015**, 50, 335-43 | 4 | 30 |
| 164 | Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. *Clinical Endocrinology*, **2015**, 82, 280-5 | 3.4 | 100 |
| 163 | Images in endocrine pathology: similar, but not the same!. *Endocrine Pathology*, **2015**, 26, 187-9 | 4.2 | 1 |
| 162 | Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. *Blood*, **2015**, 126, 950-6 | 2.2 | 111 |
| 161 | Cromogranina A e peptidi derivati: fisiopatologia e importanza clinica. *L Endocrinologo*, **2015**, 16, 116-122 | | |
| 160 | Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience. *Cytopathology*, **2015**, 26, 288-96 | 1.3 | 15 |
| 159 | Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario. *Nuclear Medicine Communications*, **2015**, 36, 1100-6 | 1.6 | 14 |
| 158 | A rare case of metastatic clear cell carcinoma of the Müllerian system originating from the peritoneum assessed by 18F-FDG PET/CT. *Clinical Nuclear Medicine*, **2015**, 40, e58-60 | 1.7 | 1 |
| 157 | Bone Marrow Involvement in Unknown Acute Myeloid Leukemia Detected by 18F-FDG PET/MRI. *Clinical Nuclear Medicine*, **2015**, 40, e486-7 | 1.7 | 4 |
| 156 | Squamous cell carcinoma of the tonsil incidentally detected by 18F-choline PET/CT. *Clinical Nuclear Medicine*, **2015**, 40, 93-5 | 1.7 | 3 |
| 155 | Metastatic undifferentiated spindle cell sarcoma of the thyroid gland evaluated by 18F-FDG PET/CT. *Clinical Nuclear Medicine*, **2015**, 40, e208-10 | 1.7 | 7 |
| 154 | Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 1301-14 | 5.9 | 33 |
| 153 | Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: a meta-analysis. *Clinical and Translational Imaging*, **2015**, 3, 133-140 | 2 | 2 |

| | | | |
|---|---|---|---|
| 152 | An Unusual Case of Plasmablastic Lymphoma Presenting as Paravertebral Mass Evaluated by (18) F-FDG PET/CT. *Nuclear Medicine and Molecular Imaging*, **2014**, 48, 89-90 | 1.9 | 5 |
| 151 | Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis. *Japanese Journal of Radiology*, **2014**, 32, 59-68 | 2.9 | 34 |
| 150 | An Unusual Case of Extraskeletal Retroperitoneal Osteosarcoma Incidentally Detected by (18)F-FDG PET/CT. *Nuclear Medicine and Molecular Imaging*, **2014**, 48, 249-50 | 1.9 | 2 |
| 149 | Small cell carcinoma of the thyroid gland with a solid brain metastasis detected by F-18-FDG PET/CT. *Endocrine*, **2014**, 46, 682-3 | 4 | 3 |
| 148 | Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. *European Journal of Endocrinology*, **2014**, 171, R33-46 | 6.5 | 72 |
| 147 | [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. *Journal of Clinical Oncology*, **2014**, 32, 1769-75 | 2.2 | 120 |
| 146 | Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 440-7 | 5.6 | 68 |
| 145 | Thyroid nodules with indeterminate cytology: molecular imaging with □mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1497-500 | 8.8 | 26 |
| 144 | □F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1482-91 | 8.8 | 21 |
| 143 | Well-differentiated follicular patterned tumors of the thyroid with high-grade features can metastasize in the absence of capsular or vascular invasion: report of a case. *International Journal of Surgical Pathology*, **2014**, 22, 749-56 | 1.2 | 9 |
| 142 | Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis. *Endocrine*, **2014**, 46, 52-9 | 4 | 44 |
| 141 | Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review. *Clinical and Translational Oncology*, **2014**, 16, 770-5 | 3.6 | 24 |
| 140 | An Unusual Case of Extramedullary Plasmacytoma of the Hypopharynx Detected by (18)F-FDG PET/CT. *Nuclear Medicine and Molecular Imaging*, **2014**, 48, 328-9 | 1.9 | 1 |
| 139 | The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review. *Academic Radiology*, **2014**, 21, 675-84 | 4.3 | 54 |
| 138 | Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2014**, 28, 507-18 | 6.5 | 35 |
| 137 | The essential use of FNA-calcitonin for detecting medullary thyroid cancer. *Endocrine*, **2014**, 47, 342-4 | 4 | 10 |
| 136 | Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. *Clinical Endocrinology*, **2014**, 80, 135-40 | 3.4 | 61 |
| 135 | Hypercalcitoninemia and thyroid nodules: when cytology (still) matters. *Diagnostic Cytopathology*, **2014**, 42, 970-3 | 1.4 | 0 |

| | | | |
|---|---|---|---|
| 134 | Medullary thyroid cancer diagnosis: an appraisal. *Head and Neck*, **2014**, 36, 1216-23 | 4.2 | 50 |
| 133 | The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. *Radiology and Oncology*, **2014**, 48, 219-27 | 3.8 | 30 |
| 132 | Prevalence and malignancy risk of focal colorectal incidental uptake detected by (18)F-FDG-PET or PET/CT: a meta-analysis. *Radiology and Oncology*, **2014**, 48, 99-104 | 3.8 | 34 |
| 131 | A rare case of mucinous cystadenoma of the lung mimicking malignancy at 18F-FDG PET/CT. *Clinical Nuclear Medicine*, **2014**, 39, e331-3 | 1.7 | 1 |
| 130 | An unusual case of diffuse large B-cell lymphoma involving the vulva evaluated by 18F-FDG PET/CT. *Clinical Nuclear Medicine*, **2014**, 39, e439-41 | 1.7 | 1 |
| 129 | Multifocal epithelioid hemangioendothelioma of the lower limbs detected by 18F-FDG PET/MRI. *Clinical Nuclear Medicine*, **2014**, 39, e402-4 | 1.7 | 8 |
| 128 | Colorectal carcinoma with bone metastases detected by 18F-choline PET/CT. *Clinical Nuclear Medicine*, **2014**, 39, e246-8 | 1.7 | 1 |
| 127 | A rare case of synchronous fetal type adenocarcinoma and mucinous adenocarcinoma of the lung evaluated by 18F-FDG PET/CT. *Clinical Nuclear Medicine*, **2014**, 39, e384-6 | 1.7 | 2 |
| 126 | Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland. Systematic review and meta-analysis on prevalence and risk of malignancy. *Nuklearmedizin - NuclearMedicine*, **2014**, 53, 249-58 | 1.8 | 28 |
| 125 | Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients. What to do with negative anatomical imaging and radioiodine scan?. *Nuklearmedizin - NuclearMedicine*, **2014** , 53, 1-10 | 1.8 | 5 |
| 124 | Current role and future perspectives of radioiodinated MIBG in the evaluation of dementia with Lewy bodies. *Current Radiopharmaceuticals*, **2014**, 7, 75-8 | 1.8 | 1 |
| 123 | Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer?. *Thyroid*, **2014**, 24, 1607-11 | 6.2 | 25 |
| 122 | Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 725-33 | 5.9 | 78 |
| 121 | La diagnostica di laboratorio delle malattie del surrene. Raccomandazioni pratiche per feocromocitoma e paraganglioma. *Rivista Italiana Della Medicina Di Laboratorio*, **2014**, 10, 193-203 | 1.1 | 1 |
| 120 | Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. *Journal of Experimental and Clinical Cancer Research*, **2014**, 33, 87 | 12.8 | 36 |
| 119 | Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers. *Hormone and Metabolic Research*, **2014**, 46, 370-4 | 3.1 | 36 |
| 118 | Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. *Academic Radiology*, **2014**, 21, 11-20 | 4.3 | 38 |
| 117 | Solitary Plasmacytoma of the Sternum Mimicking Bone Metastasis in a Patient with a History of Breast Cancer Evaluated by F-18-FDG PET/CT. *Nuclear Medicine and Molecular Imaging*, **2014**, 48, 169-70 | 1.9 | 0 |

| | | | |
|---|---|---|---|
| 116 | Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT. *Nuclear Medicine and Molecular Imaging*, **2014**, 48, 163-5 | 1.9 | 3 |
| 115 | Left atrial metastasis of H□thle-cell thyroid carcinoma mimicking myxoma. *Journal of Nuclear Cardiology*, **2014**, 21, 406-7 | 2.1 | 3 |
| 114 | Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma. *Current Medicinal Chemistry*, **2014**, 21, 3687-92 | 4.3 | 11 |
| 113 | Calcitonin measurement on fine needle washouts: preanalytical issues and normal reference values. *Diagnostic Cytopathology*, **2013**, 41, 226-9 | 1.4 | 12 |
| 112 | Letter to the editor: Lymph nodes thyroglobulin measurement after rhTSH stimulation. *Head and Neck*, **2013**, 35, 146 | 4.2 | 3 |
| 111 | A Papillary Thyroid Tumor Detected by (18)F-FDG-PET/CT in a Pediatric Patient with Cowden Syndrome. *Nuclear Medicine and Molecular Imaging*, **2013**, 47, 143-5 | 1.9 | 0 |
| 110 | CDX2 expression in columnar variant of papillary thyroid carcinoma. *Thyroid*, **2013**, 23, 1498-9 | 6.2 | 8 |
| 109 | The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. *European Archives of Oto-Rhino-Laryngology*, **2013**, 270, 1783-7 | 3.5 | 37 |
| 108 | Diagnostic performance of (99m)Tc-MIBI scan in predicting the malignancy of thyroid nodules: a meta-analysis. *Endocrine*, **2013**, 44, 70-8 | 4 | 51 |
| 107 | Usefulness of □F-FDG PET/CT in syphilitic aortitis. *Clinical Rheumatology*, **2013**, 32, 1247 | 3.9 | |
| 106 | 131I whole-body scan or 18FDG PET/CT for patients with elevated thyroglobulin and negative ultrasound?. *Clinical and Translational Imaging*, **2013**, 1, 175-183 | 2 | 10 |
| 105 | Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis. *American Journal of Clinical Dermatology*, **2013**, 14, 437-47 | 7.1 | 48 |
| 104 | Toxoplasmic Lymphadenitis Mimicking a Metastatic Thyroid Carcinoma at (18)F-FDG-PET/CT. *Nuclear Medicine and Molecular Imaging*, **2013**, 47, 289-90 | 1.9 | 2 |
| 103 | Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. *Thyroid*, **2013**, 23, 1211-25 | 6.2 | 120 |
| 102 | Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 40, 874-80 | 8.8 | 69 |
| 101 | Incidental detection of H□thle cell adenoma by 18F-choline PET/CT scan in a patient with prostate cancer. *Revista Espanola De Medicina Nuclear E Imagen Molecular*, **2013**, 32, 340-1 | 0.4 | 8 |
| 100 | Thyrotropin values in patients with micropapillary thyroid cancer versus benign nodular disease. *Endocrine Practice*, **2013**, 19, 651-5 | 3.2 | 10 |
| 99 | Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: a systematic review and a meta-analysis. *Foot*, **2013**, 23, 140-8 | 1.3 | 51 |

| | | | |
|---|---|---|---|
| 98 | Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 1477-81 | 5.9 | 30 |
| 97 | Unusual muscular metastases from papillary thyroid carcinoma detected by fluorine-18-fluorodeoxyglucose PET/MRI. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2208-9 | 5.6 | 2 |
| 96 | High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?. *Hormone and Metabolic Research*, **2013**, 45, 664-8 | 3.1 | 14 |
| 95 | The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. *International Journal of Endocrinology*, **2013**, 2013, 856189 | 2.7 | 44 |
| 94 | Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer. *Current Opinion in Oncology*, **2013**, 25, 6-13 | 4.2 | 40 |
| 93 | Evaluation of the BRAHMS Kryptor( ) thyroglobulin minirecovery test in patients with differentiated thyroid carcinoma. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 449-53 | 5.9 | 15 |
| 92 | Relationship between antithyroglobulin autoantibodies and thyroglobulin recovery rates using different thyroglobulin concentrations in the recovery buffer. *Hormone and Metabolic Research*, **2013**, 45, 728-35 | 3.1 | 11 |
| 91 | Prevalence and risk of malignancy of thyroid incidentalomas detected by (18)f-fluorodeoxyglucose positron-emission tomography. *Thyroid*, **2013**, 23, 124-6 | 6.2 | 12 |
| 90 | Thyroid lobe ablation with iodine- I in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities. *Nuclear Medicine Communications*, **2013**, 34, 767-70 | 1.6 | 16 |
| 89 | Radioguided surgery of thyroid carcinoma recurrences: the role of preoperative (99m)Tc-labeled human serum albumin macroaggregates-SPECT/CT mapping. *Clinical Nuclear Medicine*, **2013**, 38, e207-9 | 1.7 | 6 |
| 88 | When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer. *Cancer Management and Research*, **2013**, 5, 123-31 | 3.6 | 6 |
| 87 | Focal thyroid incidental uptake detected by F-fluorodeoxyglucose positron emission tomography. Meta-analysis on prevalence and malignancy risk. *Nuklearmedizin - NuclearMedicine*, **2013**, 52, 130-6 | 1.8 | 38 |
| 86 | Iodine-131 administration and risk of cancer: "appearances can be deceptive". *Hormones*, **2013**, 12, 312-4 | 3.1 | 0 |
| 85 | PET and PET/CT imaging in thyroid and adrenal diseases: an update. *Hormones*, **2013**, 12, 327-33 | 3.1 | 7 |
| 84 | Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer. *European Journal of Endocrinology*, **2012**, 167, 793-7 | 6.5 | 14 |
| 83 | Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. *Head and Neck*, **2012**, 34, 626-31 | 4.2 | 39 |
| 82 | Multiplexed immunoassay of thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma. *Head and Neck*, **2012**, 34, 1369-71 | 4.2 | 6 |
| 81 | Images in endocrine pathology: a starry-sky in the thyroid. *Endocrine Pathology*, **2012**, 23, 79-81 | 4.2 | 4 |

| | | | |
|---|---|---|---|
| 80 | Evaluation of the BRAHMS KRYPTOR thyroglobulin "mini-recovery" test in thyroid healthy subjects. *Hormone and Metabolic Research*, **2012**, 44, 555-7 | 3.1 | 7 |
| 79 | Serum procalcitonin and calcitonin normal values before and after calcium gluconate infusion. *Experimental and Clinical Endocrinology and Diabetes*, **2012**, 120, 169-70 | 2.3 | 18 |
| 78 | Ectopic substernal thyroid tissue: a challenging differential diagnosis. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 719-20 | 5.6 | 23 |
| 77 | Serum thyroglobulin reference values according to NACB criteria in healthy subjects with normal thyroid ultrasound. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 891-3 | 5.9 | 14 |
| 76 | PET Imaging in Recurrent Medullary Thyroid Carcinoma. *International Journal of Molecular Imaging*, **2012**, 2012, 324686 | | 30 |
| 75 | Medullary thyroid nodules by measurement of calcitonin (Ct) in aspiration needle washout in patients with multinodular goiter and moderately elevated serum Ct. *Experimental and Clinical Endocrinology and Diabetes*, **2012**, 120, 234-7 | 2.3 | 16 |
| 74 | Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 895-900 | 5.9 | 16 |
| 73 | 18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. *Clinical Nuclear Medicine*, **2012**, 37, 949-52 | 1.7 | 19 |
| 72 | Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. *Expert Review of Endocrinology and Metabolism*, **2012**, 7, 35-43 | 4.1 | 8 |
| 71 | Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. *Blood*, **2012**, 120, 1566-1566 | 2.2 | 2 |
| 70 | Radioiodine Therapy: Current Imaging Concepts Introduction **2012**, 224-230 | | |
| 69 | Thyroid remnant estimation by Tc-99m-sestamibi scanning predicts the effectiveness of rhTSH-stimulated I-131 ablation in patients with differentiated thyroid carcinoma. *Clinical Nuclear Medicine*, **2011**, 36, 781-5 | 1.7 | 3 |
| 68 | Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. *Clinical Nuclear Medicine*, **2011**, 36, 109-12 | 1.7 | 37 |
| 67 | 18FDG-positron emission tomography/computed tomography (PET/CT) scanning in thyroid nodules with nondiagnostic cytology. *Clinical Endocrinology*, **2011**, 74, 644-8 | 3.4 | 24 |
| 66 | Evaluation of serum parathyroid hormone-related peptide in hyperthyroid patients. *European Journal of Clinical Investigation*, **2011**, 41, 93-7 | 4.6 | 2 |
| 65 | Paratormone e Vitamina D. *Rivista Italiana Della Medicina Di Laboratorio*, **2011**, 7, 140-143 | 1.1 | |
| 64 | Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules. *Head and Neck*, **2011**, 33, 95-7 | 4.2 | 22 |
| 63 | Postsurgical thyroid remnant estimation by (□□m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. *Head and Neck* , **2011**, 33, 552-6 | 4.2 | 20 |

| | | | |
|---|---|---|---|
| 62 | Thyroglobulin-guided (131)I ablation in low-risk differentiated thyroid carcinoma: is the yardstick accurate enough?. *Head and Neck*, **2011**, 33, 1379-80; author reply 1380-1 | 4.2 | 2 |
| 61 | Ruling out 131I ablation in low-risk differentiated thyroid carcinoma basing on thyroglobulin measurement. *Thyroid*, **2011**, 21, 809-10; author reply 811-2 | 6.2 | 1 |
| 60 | Could different hydration protocols affect the quality of 18F-FDG PET/CT images?. *Journal of Nuclear Medicine Technology*, **2011**, 39, 77-82 | 1.1 | 11 |
| 59 | Lymph node thyroglobulin measurement in diagnosis of neck metastases of differentiated thyroid carcinoma. *Journal of Thyroid Research*, **2011**, 2011, 621839 | 2.6 | 26 |
| 58 | Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 1025-7 | 5.9 | 14 |
| 57 | Thyroglobulin and thyroglobulin autoantibodies measurement using the automated KRYPTOR platform in patients with differentiated thyroid carcinoma. *Hormone and Metabolic Research*, **2011**, 43, 728-30 | 3.1 | 4 |
| 56 | False-positive calcitonin results in patients with benign goiter. *Clinical Chemistry and Laboratory Medicine*, **2011**, 50, 407-8 | 5.9 | 2 |
| 55 | Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. *Tumori*, **2011**, 97, 629-33 | 1.7 | 9 |
| 54 | Interference in thyroid-stimulating hormone determination. *European Journal of Clinical Investigation*, **2010**, 40, 756-8 | 4.6 | 17 |
| 53 | Hyperfunctioning solid/trabecular follicular carcinoma of the thyroid gland. *Journal of Oncology*, **2010**, 2010, | 4.5 | 9 |
| 52 | Three-dimensional ordered-subset expectation maximization iterative protocol for evaluation of left ventricular volumes and function by quantitative gated SPECT: a dynamic phantom study. *Journal of Nuclear Medicine Technology*, **2010**, 38, 18-23 | 1.1 | 8 |
| 51 | Spurious increase in serum chromogranin A: the role of heterophilic antibodies. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1497-9 | 5.9 | 4 |
| 50 | Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. *Hormone and Metabolic Research*, **2010**, 42, 736-9 | 3.1 | 41 |
| 49 | Circulating procalcitonin in aseptic carcinoma patients: a specificity study with (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1163-5 | 5.9 | 8 |
| 48 | Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. *Head and Neck*, **2010**, 32, 568-71 | 4.2 | 26 |
| 47 | (99m)Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. *Head and Neck*, **2010**, 32, 607-11 | 4.2 | 30 |
| 46 | Elevated calcitonin and procalcitonin levels in nonmedullary benign and malignant thyroid nodules. *Clinical Endocrinology*, **2010**, 72, 852-3 | 3.4 | 5 |
| 45 | Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 1039-40; author reply 1041-2 | 8.8 | 6 |

| | | | |
|---|---|---|---|
| 44 | Thyroid metastases from typical carcinoid of the lung differentiating between medullary thyroid carcinoma and neuroendocrine tumor metastasis to the thyroid. *Thyroid*, **2009**, 19, 521-6 | 6.2 | 12 |
| 43 | Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 952-4 | 5.9 | 44 |
| 42 | Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1001-4 | 5.9 | 25 |
| 41 | Thyroglobulin measurement on fine-needle washout fluids: Influence of sample collection methods. *Diagnostic Cytopathology*, **2009**, 37, 42-4 | 1.4 | 30 |
| 40 | False-negative thyroglobulin measurement in recurrent/metastatic thyroid carcinomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 326-7; author reply 328 | 8.8 | 9 |
| 39 | Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. *Clinical Endocrinology*, **2008**, 69, 659-63 | 3.4 | 50 |
| 38 | Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) with negative thyroperoxidase antibodies. *European Journal of Clinical Investigation*, **2008**, 38, 693-4 | 4.6 | 5 |
| 37 | Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 1067-73 | 5.9 | 39 |
| 36 | A hypothyroid patient with increased free thyroid hormones. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 1650-1 | 5.9 | 1 |
| 35 | Thyroglobulin measurement in differentiated thyroid carcinoma management. *Expert Review of Endocrinology and Metabolism*, **2008**, 3, 117-125 | 4.1 | 1 |
| 34 | Second-generation thyrotropin receptor antibodies assay and quantitative thyroid scintigraphy in autoimmune hyperthyroidism. *Hormone and Metabolic Research*, **2008**, 40, 484-6 | 3.1 | 13 |
| 33 | Graves' disease, thymus enlargement, and hypercalcemia. *New England Journal of Medicine*, **2008**, 358, 1078-9 | 59.2 | 8 |
| 32 | Simultaneous imaging of pericardial thymoma and parathyroid adenoma by sestamibi scan. *Clinical Nuclear Medicine*, **2008**, 33, 542-4 | 1.7 | 4 |
| 31 | 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS. *Nuclear Medicine Communications*, **2008**, 29, 535-41 | 1.6 | 9 |
| 30 | Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. *International Journal of Biological Markers*, **2008**, 23, 54-7 | 2.8 | 12 |
| 29 | Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers. *International Journal of Biological Markers*, **2008**, 23, 129-31 | 2.8 | 14 |
| 28 | Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 52, 84-88 | 1.4 | 2 |
| 27 | Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. *Clinical Endocrinology*, **2007**, 67, 547-51 | 3.4 | 17 |

| | | | |
|---|---|---|---|
| 26 | Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma. *Clinical Chemistry*, **2007**, 53, 1871-2 | 5.5 | 34 |
| 25 | Imaging in endocrinology: Langherans cell histiocytosis of the thyroid gland detected by 18FDG-PET/CT. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 2866-7 | 5.6 | 8 |
| 24 | Redefining functional sensitivity of thyroglobulin assay on Immulite platform: implications in thyroid cancer management. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45, 1523-4 | 5.9 | 4 |
| 23 | F-18 FDG PET-CT imaging in the care-management of a patient with pan-aortitis and coronary involvement. *Clinical Nuclear Medicine*, **2007**, 32, 562-4 | 1.7 | 8 |
| 22 | False-positive serum chromogranin A assay due to heterophile antibody interference. *Clinica Chimica Acta*, **2007**, 379, 171-2 | 6.2 | 12 |
| 21 | Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. *Clinical Chemistry and Laboratory Medicine*, **2006**, 44, 648-52 | 5.9 | 32 |
| 20 | Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 50, 344-7 | 1.4 | 22 |
| 19 | Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. *Clinical Chemistry and Laboratory Medicine*, **2005**, 43, 843-7 | 5.9 | 35 |
| 18 | Serum chromogranin-A assay in differential diagnosis of incidentally discovered adrenal masses. *Anticancer Research*, **2005**, 25, 1547-50 | 2.3 | 7 |
| 17 | Natriuretic peptides as markers of preclinical cardiac disease in obesity. *European Journal of Clinical Investigation*, **2004**, 34, 342-8 | 4.6 | 33 |
| 16 | High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. *Clinical Chemistry and Laboratory Medicine*, **2002**, 40, 480-4 | 5.9 | 21 |
| 15 | Serum chromogranin-alpha immunoradiometric assay in the diagnosis of pheochromocytoma. *International Journal of Biological Markers*, **2002**, 17, 130-4 | 2.8 | 5 |
| 14 | Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase. *International Journal of Biological Markers*, **2001**, 16, 50-5 | 2.8 | 2 |
| 13 | Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. *International Journal of Biological Markers*, **2001**, 16, 268-72 | 2.8 | 9 |
| 12 | Late blood pool images after Tc-99m tetrofosmin injection in a patient with monoclonal gammopathy of uncertain significance and immunologic disorders. *Clinical Nuclear Medicine*, **2000**, 25, 536-8 | 1.7 | |
| 11 | "False-positive" myocardial perfusion scintigraphy findings in patients with angiographically normal coronary arteries: insights from intravascular sonography studies. *Journal of Nuclear Medicine*, **2000** , 41, 1935-40 | 8.9 | 41 |
| 10 | Chromogranin-A as a Serum Marker for Neuroendocrine Tumors: Comparison with Neuron-Specific Enolase and Correlation with Immunohistochemical Findings. *International Journal of Biological Markers*, **1999**, 14, 160-166 | 2.8 | 28 |
| 9 | Diagnostic criteria for detection of postinfarction ischemia by quantitative analysis of stepwise dobutamine radionuclide ventriculography. *Journal of Nuclear Cardiology*, **1999**, 6, 514-21 | 2.1 | 2 |

| | | | |
|---|---|---|---|
| 8 | Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. *International Journal of Biological Markers*, **1999**, 14, 160-6 | 2.8 | 4 |
| 7 | Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. *Nuclear Medicine Communications*, **1997**, 18, 1087-97 | 1.6 | 36 |
| 6 | Relationship between left ventricular diastolic function and atrial natriuretic factor in never-treated mild hypertensives. *American Journal of Hypertension*, **1997**, 10, 946-50 | 2.3 | 7 |
| 5 | Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. *International Journal of Biological Markers*, **1997**, 12, 22-6 | 2.8 | 6 |
| 4 | Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA). *International Journal of Biological Markers*, **1997**, 12, 27-34 | 2.8 | 2 |
| 3 | Assessment of myocardial area at risk by technetium-99m sestamibi during coronary artery occlusion: comparison between three tomographic methods of quantification. *European Journal of Nuclear Medicine and Molecular Imaging*, **1996**, 23, 31-9 | | 19 |
| 2 | Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. *International Journal of Biological Markers*, **1995**, 10, 156-60 | 2.8 | 1 |
| 1 | Diagnostica del nodulo tiroideo autonomo: è sufficiente misurare il TSH?. *L Endocrinologo*,1 | 0 | |